Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at Roth Capital

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Roth Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $31.00 price objective on the biotechnology company's stock. Roth Capital's price objective suggests a potential upside of 141.43% from the company's current price.

Several other research analysts also recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Friday. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock traded up $0.46 during trading on Tuesday, hitting $12.84. 1,776,118 shares of the stock were exchanged, compared to its average volume of 1,825,515. The firm's 50-day moving average price is $10.80 and its 200 day moving average price is $12.64. The stock has a market cap of $586.49 million, a price-to-earnings ratio of -12.16 and a beta of 0.84. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. During the same quarter last year, the company earned ($0.31) EPS. As a group, research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. raised its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $68,000. AlphaQuest LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund boosted its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.